|
2007 - Detail
November
Paladin Reports 2007 Record Third Quarter Financial Results. Paladin announced that it has submitted a patent application for its novel oral ingestible film composition delivery system, ThinsolTM. Paladin announced that they have been selected for induction in the 2007 Canadian Healthcare Marketing Hall of Fame.
September
Paladin Labs Inc. and Labopharm Inc. announced the Canadian launch of TriduralTM once-daily tramadol product.
August
Paladin announced that it has expanded its current exclusive Canadian distribution agreement with Shire Human Genetic Therapies, Inc. (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ). Paladin announced that it has entered into an exclusive license and distribution agreement with Glide Pharmaceutical Technologies Limited (Glide PharmaTM) to develop and market Glide Pharma's innovative Glide SDITM (Solid Dose Injector) needle-free drug delivery products in Canada.
July
Paladin announced that it has obtained Health Canada's approval for SEASONALETM - the first and only extended-cycle oral contraceptive available in this country. Paladin announced that they have completed a licensing and distribution agreement under which Labopharm has granted Paladin the exclusive right to market and sell Labopharm's once-daily tramadol product in Canada.
May
Paladin Labs Inc., through its wholly owned subsidiary, Squire Pharmaceuticals Inc. today announced that it has entered into an agreement with Shire BioChem Inc., Shire US Inc. Paladin Reports 2007 First Quarter Financial Results & Increases Revenue Guidance. Paladin announced that it has acquired, through its wholly-owned subsidiary, Squire Pharmaceuticals Inc, Zincofax®, one of Canada's leading diaper rash creams, from Johnson & Johnson, Inc.
April
Paladin proudly announced that the Company won two Genesis awards. Paladin won the Biotechnology/Biopharmaceutical Entrepreneurship Award for outstanding growth and Jonathan Ross Goodman, President & CEO, won the BRIO Award for significant contribution to the development of the life sciences industry. Paladin announced the approval by Health Canada of a new one-step dosing regimen for Plan B®. Paladin announced the closing of the purchase of BioEnvelop Inc. a wholly owned subsidiary of BioEnvelop Technologies Inc. (TSX-V:BIE).
February
Paladin reported its financial results for the fourth quarter and year ended December 31, 2006. The Company achieved record revenues for the fourth quarter of 2006 and has achieved its 11th consecutive year of record revenues.
January
Paladin Labs and Stallergenes SA announced that they have entered into a Canadian development, promotion and distribution agreement for OralairTM, Stallergenes' allergen extract immunotherapy sublingual tablets.Paladin announced the commercial launch of PravASA®, an innovative, cost-effective product which combines pravastatin, a cholesterol-lowering medication, and delayed-release ASA, a platelet aggregation inhibitor, in a single package.
2006 - Detail
December
Paladin announced that it will assume Canadian Pennsaid® (topical diclofenac) sales and marketing responsibilities from Solvay Pharma Inc. effective December 1, 2006. Paladin acquired the Canadian rights to Pennsaid® from Nuvo Research Inc. which included a co-promotional agreement with Solvay Pharma Inc
Paladin reported its right to enter into a license with Nuvo Research Inc. (TSX:NRI) to market and sell Pennsaid® Plus in Canada.
Paladin announced that it has entered into an exclusive Canadian distribution agreement with Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) to market Testim®, a testosterone gel approved by Health Canada and indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
November
Paladin reported its unaudited financial results for the three and nine-month periods ended September 30, 2006. The Company achieved record revenues for the third quarter and first nine months of 2006 and is well positioned to achieve its 11th consecutive year of record revenues in 2006.
Paladin announced that it will be expanding its presence in the growing Canadian pain market through the addition of Vicoprofen® and Metadol® to its product line
August
Paladin announced record revenues for the three and six-month periods ended June 30, 2006. The Company also reported increased revenue guidance for fiscal 2006, a result of stronger than expected sales from key promoted brands.
May
Paladin reported its 2006 first quarter financial results.
April
Paladin won the Mercuriades Award for the best company in the Trade and Distribution Category. This refers to the exceptional quality of performance in the company's overall management in the retail or distribution sector. The Mercuriades is an annual competition organized the Quebec Federation of Chambers of Commerce to honor and support excellence in Quebec business.
Paladin donated nearly $300,000 in medication to Health Partners International of Canada (HPIC). The medication is destined for Nicaragua, one of the poorest countries in Latin America. This is vital support for HPIC's mission of improving the health of people in developing nations.
March
Paladin announced that Health Canada has approved VANTAS®, a unique, once-yearly luteinizing hormone-releasing hormone (LHRH) implant indicated for the palliative treatment of advanced prostate cancer, the most prevalent form of cancer afflicting Canadian men.
February
Paladin reported its financial results for the fourth quarter and year ended December 31, 2005. Supported by strong fourth quarter financial performance, the Company exceeded its 2005 financial guidance for revenue. Paladin reported its financial results for the fourth quarter and year ended December 31, 2005. Supported by strong fourth quarter financial performance, the Company exceeded its 2005 financial guidance for revenue.
January
Paladin and Nuvo Research Inc. jointly announced that they have entered into an agreement which expands their relationship with respect to the sale and marketing of Pennsaid® in Canada.
2005 - Detail
October
Paladin announced that it has entered into an exclusive agreement with Duramed Pharmaceuticals, Inc. a subsidiary of Barr Pharmaceuticals, Inc. for the licensing and distribution of Seasonale in Canada. Paladin reported record revenues for the third quarter September 30, 2005.
September
Paladin announced the Canadian launch of TwinjectT, a novel epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis).
August
Paladin announced that it has acquired Dimethaid Health Care Ltd. (DHCL), a subsidiary of Dimethaid Research Inc. (TSX: DMX). DHCL owns the Canadian license for Pennsaid®, a lotion approved by Health Canada for the treatment of symptoms of knee osteoarthritis.
July
Paladin announced that it has entered into an exclusive agreement with Verus Pharmaceuticals, Inc. for commercialization of Twinject in Canada. Paladin reported its financial results for the second quarter June 30, 2005.
June
Health Canada requests additional information on Vantas New Drug Submission.
May
Paladin announced that it has entered into a Canadian marketing and supply agreement with Watson Pharma, Inc. to market Trelstar® 3.75 mg and Trelstar® LA 11.25 mg. Paladin announced its results for the first quarter of 2005.
April
Paladin confirmed that Plan B is now available at Canadian pharmacies without a prescription.
March
Paladin announced the appointment of Dr. Patrice Larose as Vice-President, Regulatory Affairs, Drug Safety and Medical Services.
February
Paladin announced The Conseil du médicament of Quebec has given its approval to list Oxytrol®. Paladin announced that it has received regulatory approval from the Toronto Stock Exchange to carry out a normal course issuer bid effective February 22, 2005. Paladin reported its financial results for the fourth quarter and year ended December 31, 2004. Supported by strong fourth quarter financial performance, the Company exceeded its 2004 financial guidance for revenue, EBITDA and net income.
2004 - Detail
October
Paladin makes generous donation to HPIC in support of humanitarian aid efforts overseas. Paladin announces Canadian launch of Oxytrol®. Paladin announced its third quarter results. Revenue for the third quarter totaled a record $7.9 million, a 46% increase compared to Q3 2003. Net income for the third quarter increased to $1.0 million from net income of $356,000 in Q3 2003.
September
Paladin realigned its product pipeline and announced a change to the Management Team. Paladin signed a marketing agreement with Duramed Pharmaceuticals for two women's health products.
July
Paladin filed a New Drug Submission for Histrelin Hydrogel Implant. Paladin filed a New Drug Submission for GlucaGen®. Paladin announced its second quarter results. Revenue for the second quarter totaled $6.4 million, down slightly from a record $6.5 million in the second quarter of 2003. Net income for the second quarter was $681,000 or $0.05 per fully diluted share, compared to a net loss of $142,000 or ($0.01) per share in the second quarter a year ago.
June
Health Canada approved OXYTROL®, an innovative patch for overactive bladder treatment (OAB).
May
Paladin announced its results for the first quarter of 2004. Revenue increased 11% to $5.6 million, compared to $5.1 million in the first quarter of 2003. Net income for the quarter was $344,000 or $0.02 per fully diluted share, compared to net income of $573,000 or $0.04 per fully diluted share in the first quarter a year ago. Health Canada proposed amending regulations to allow access to Plan B® without a prescription. Paladin signed distribution agreement with Ovation Pharmaceuticals for two central nervous system drugs.
March
Paladin appointed Mr. Gerald P. McDole to its Board of Directors.
February
Paladin announced its financial results for the year ended December 31, 2003. Total revenues increased $504,000 to a record $25.9 million from $23.4 million in 2002. Paladin recorded a net loss of $4.2 million, primarily attributable to one-time charges resulting from the write-down of the carrying value of certain assets and increased marketing and promotion expenses supporting key products. Paladin signed an exclusive distribution agreement for ReplagalT with Transkaryotic Therapies, Inc.
January
Paladin entered into a licensing agreement with Watson Pharmaceuticals for OXYTROL® in Canada.
2003 - Summary
Total revenues increased $504,000 to $23.9 million from $23.4 million in 2002. During the year, Paladin successfully concluded licensing and distribution agreements for five brand name pharmaceuticals (Sandomigran®, Sintrom®, Zaditen®, Cortifoam® and Darvon-N®), and two late-stage development products (Diacol® and OXYTROL®). Furthermore, Health Canada recommended the switch from prescription to non-prescription status for Plan BT. Paladin received orphan drug designation in Europe for Fidelin® (DHEA) and FDA orphan drug designation for Fidelin® in the U.S.
2003 - Detail
December
Health Canada requested additional information on CIRCADIN® new drug submission.
Paladin acquired rights in Canada for DARVON-N® from Eli Lilly and Company.
Health Canada requested additional information on STATEX® SR new drug submission.
Paladin announced 2004 Financial Outlook and revised 2003 Financial Guidance.
November
Paladin and PanGeo Pharma signed a distribution agreement for a portfolio of products including Sandomigran®, Sintrom®, and Zatiden®. Paladin and Meda announced a Canadian distribution agreement for Cortifoam®.
October
Paladin's Co-Founders named Quebec Entrepreneurs of the Year in the Health Care / Life Sciences field. Paladin released its financial results for its third quarter. Revenues reached $5.4 million, a decrease of 11% over the same period last year. Net income was $381,000 or $0.03 per share, compared to net income of $1.5 million or $0.10 per share in the third quarter a year ago.
August
Paladin received orphan drug designation in Europe for Fidelin® (DHEA). Paladin received FDA orphan drug desination for FidelinT (DHEA) in the United States.
July
Paladin announced its financial results for the second quarter of 2003. Revenues for the second quarter increased 13% to $6.5 million compared to $5.7 million in the second quarter a year ago.
Net income, excluding write-downs, was $1.4 million or $0.10 per share for the second quarter of 2003 and 2002. Net income, excluding write-downs, was $2.1 million or $0.14 per share for the first half of 2003 compared to net income of $2.8 million or $0.22 per share in the corresponding period last year.
June
Health Canada recommended emergency contraceptive pill, Plan BT, for switch to non-prescription status.
May
Paladin appointed two new directors to its Board, with the appointments of Aldo R. Baumgartner, Ph.D., and Michael S. Cloutier. Prior to joining Paladin's Board, Dr. Baumgartner was President & CEO of Wyeth-Ayerst Canada Inc. and Mr. Cloutier was President of Pharmacia Canada Inc. Paladin announced its results for the first quarter of 2003. Revenues declined 5% to $5.1 million, compared to $5.3 million in the first quarter of 2002. Net income was $672,000 or $0.05 per share, compared to net income of $1.4 million or $0.11 per share in the first quarter of 2002. Paladin licensed Diacol® from InKine Pharmaceutical Company, Inc.
March
Paladin transferred the rights for several OTC brands to Pharmascience Inc. This included the licenses to Sialor® and the Baker Cummins line of dermatology products, as well as the Moi-Stir® Trademark.
February
Revenues for the fourth quarter of 2002 were $6.2 million, an increase of $1.3 million or 26%, compared to $4.9 million in the fourth quarter a year ago. Net income for the fourth quarter of 2002 was $788,000 or $0.05 per diluted share, compared to a net loss of $1.5 million or $0.12 per diluted share in the same period a year ago.
2002 - Summary
Paladin continued its 7th consecutive year of record revenues, climbing 31% to $23.4 million and generating net income of $5.2 million. Paladin launched 10 new products, including Dostinex®, Estring®, Androderm® in a 5 mg format, Rogitine® and the Locacorten®-Vioform® line of products. The Company successfully completed a $21 million special warrant private placement. Paladin submitted an application to Health Canada to change Plan BT from prescription-only status to non-prescription status. The Company in-licensed the rights for 2 late-stage development products, GlucaGen® and Histrelin Hydrogel Implant. Paladin's achievements were recognized by Deloitte & Touche as Paladin was named to the 2002 Deloitte & Touche Canadian Technology Fast 50, a ranking of the top 50 fastest growing technology companies in Canada. The Company expanded to 45 employees.
2002 - Detail
December
Paladin returned the rights for DepoCytT to SkyePharma.
October
Paladin signed a license agreement with Valera Pharmaceuticals, Inc. for Histrelin Hydrogel Implant, a once-yearly implant for the palliative treatment of advanced prostate cancer. Dr. Tom Koutsavlis was appointed to the position of Vice-President, Scientific Affairs. Paladin announced record third quarter results. Total revenues increased 25% for the third quarter to a record $6.09 million. Net income increased 4% for the third quarter to a record $1.53 million.
August
Paladin named to Deloitte & Touche's prestigious "Canadian Technology Fast 50" Awards program, a ranking of the fastest growing technology companies in Canada.
September
Paladin filed a new drug submission with Health Canada for approval of Statex® SR.
Paladin and Novo Nordisk signed a distribution agreement for GlucaGen®, which is chemically identical to human glucagons, a naturally occurring peptide that selectively converts liver glycogen to glucose, relaxes smooth muscle, and increases the strength of cardiac contractions.
July
Paladin received request from Health Canada for additional information for Plan BT non-prescription switch submission. Paladin announced strong second quarter results. Total revenues increased 26% to $5.7 million and net income increased 45% for the second quarter to $1.4 million.
June
Health Canada approved Androderm® 5mg format for the treatment of male testosterone deficiency.
May
Paladin announced record first quarter results. Total revenues increased 73% for the first quarter to $6.0 million and net income increased 172% to $1.4 million.
March
Paladin announced the closing of a $21 million private placement Co-led by CIBC World Markets Inc., Yorkton Securities Inc., and including Desjardins Securities Inc., BMO Nesbitt Burns Inc., National Bank Financial Inc. and Sprott Securities Inc.
February
Paladin announced gross revenues for 2001 up 41% over 2000. Net income stood at $1.5 million, a decrease caused by a one-time write-down of intellectual property. Health Canada accepted RemodulinT for a priority drug review.
January
Paladin began the New Year by announcing its largest rights acquisition to date in a $8 million deal with Pharmacia Canada Inc. The deal was for a portfolio of endocrinology and women's health brands including Estring®, Dostinex®, Prostin®, Prepidil® and Dalacin-V®.
2001 - Summary
Paladin's strategy of acquiring and/or in-licensing innovative pharmaceuticals in late stage clinical development continued to reap dividends as the Company recorded its 6th consecutive year of record revenues. Six new products were added during the year and nine new products were launched. Our success was formally recognized, as the National Post named Paladin one of Canada's 50 Best Managed Companies. The company expanded to 36 employees. Key brands launched in 2001 included Androderm®, Oesclim®, MUSE®, ValtaxinT and Plan BT.
2001- Detail
December
The National Post named Paladin one of Canada's 50 Best Managed Companies. Paladin announced the TPD's approval for an additional methanol poisoning indication for Antizol®.
November
Paladin acquired exclusive Canadian distribution rights for Rogitine® (hypertension, erectile dysfunction) from Novartis Pharmaceuticals Canada Inc. Third quarter results were announced and net income was confirmed at $1.5 million, and revenues at $4.9 million, up 80% and 60%, respectively, from the third quarter of 2000.
August
Paladin acquired exclusive Canadian distribution rights for Propyl-Thyracil® (hyperthyroidism) from Merck Frosst Canada & Co.
July
Paladin announced that effective immediately, Samira Sakhia will take over the post of CFO.
May
First quarter net income was confirmed at $515,483 or 72.6% higher than net income for first quarter of 2000.
March
Paladin acquired exclusive Canadian distribution rights for Fiorinal® (migraine headaches) from Novartis Pharmaceuticals Canada Inc.
February
Paladin acquired exclusive Canadian distribution rights to Oesclim®, the estrogen patch from Laboratoires Fournier S.A. Paladin announced the departure of CFO Lennie Ryer.
 
2000 - Summary
In 2000, Paladin migrated from the Vancouver to the Toronto Stock Exchange under the symbol PLB and completed a $20.3 million financing. Paladin began to develop a new franchise - endocrinology - by securing the rights to Androderm® and Tapazole®. Late stage clinical studies of numerous products were ongoing as Paladin honed its ability to rapidly obtain Canadian regulatory approval for its products (ie. ValtaxinT and Antizol®). The year 2000 marked the 5th consecutive year of record revenues and net income with revenues climbing 12.5% and net income growing by 38%. Paladin's outstanding record of growth was recognized by Profit Magazine, which ranked Paladin as one of Canada's "hottest start-ups" in 2000.
2000 - Detail
December
Paladin acquired Canadian rights to Tapazole® (hyperthyroidism) from Eli Lilly & Co.
November
Paladin acquired exclusive Canadian distribution rights for MUSE®, a treatment for erectile dysfunction from VIVUS, Inc.
October
Third quarter results confirmed a higher revenue than the third quarter of 1999, but a lower net income at $819,210 or down 2 cents a share.
September
Paladin announced its sub-licensing of BioSante Pharmaceuticals, Inc.'s portfolio of female hormone replacement therapies.
August
Second quarter net income was confirmed at $1,130,378, slightly lower than the second quarter of 1999. This was due to costs associated to new product launches.
July
Paladin acquired exclusive Canadian distribution rights for SkyePharma's treatment of lymphomatous or neoplastic meningitis - DepocytT - as well as AptosynT (precancerous cancer polyps) from Cell Pathways, Inc.
May
First quarter net revenues were announced at $298,662. The lower net revenue was due to increased product launch expenses and accruing R&D costs. Paladin acquired exclusive Canadian distribution rights for Watson Laboratories, Inc.'s testosterone patch - Androderm®.
April
Paladin announced the completion of the issuance of 2,900,000 common shares at $7.00 to the public.
March
Paladin announced a public offering of shares, led by CIBC World Markets. Paladin announced 1999 year-end results, gross revenues being $11.2 million and net revenues being $2.8 million.
February
Paladin, sponsored by CIBC World Markets, began trading on the Toronto Stock Exchange.
1999 - Summary
Paladin added over 20 new products in 1999, established valuable partnerships with emerging biotech and pharmaceutical companies, and expanded the Company with talented, motivated employees. Paladin posted record revenues and profits with revenues increasing by 86% to $11.2 million and net income increasing by 141% to $2 million. As part of its commitment to enhance the liquidity of its shares, Paladin applied for listing on the Toronto Stock Exchange.
1999 - Detail
December
Paladin acquired exclusive Canadian distribution rights for Plan BT, an oral emergency contraceptive, from Women's Capital Corporation. Paladin announced the signing of an agreement to acquire Neuroscience Pharma Inc. for $3 million. It also announced the acquisition of a line of dermatology products from Baker Norton Pharmaceuticals Inc. The Dynamic QSSP Fund acquired 72,500 shares in Paladin, through a private placement.
November
Paladin received conditional listing with the Toronto Stock Exchange. CIBC World Markets is its sponsor. Paladin announced the appointment of Dr. Katia Betito as the Executive Director of Scientific Affairs.
October
Paladin acquired Nitrol® (chronic angina) from Rhone Poulenc Rorer Canada Inc. (now called Aventis S.A.). Paladin completed a deal for the exclusive Canadian distribution rights of ValtaxinT, a treatment for bladder cancer, from Anthra Pharmaceuticals, Inc. Third quarter cumulative results showed an overall improvement of 144% in net revenue from 1998 to 1999.
to acquire 162,790 common shares of Paladin Labs Inc.
September
Synsorb announced an exclusive licensing agreement with Paladin for the distribution of SYNSORB Cd®, used to treat CDAD. Paladin also announced its exclusive deal with Laboratories for Applied Biology Ltd. for the Canadian distribution of CerumolT, a product used to remove earwax. David MacNaughtan joined the Company as Vice President of Business Development effective September 20th.
August
Second quarter net income was confirmed at $1,375,411 or up 574% from the second quarter of 1998. Paladin completed the purchase of Ridaura from Pharmascience in exchange for 116,804 shares in Paladin. The Company also completed an exclusive Canadian distribution deal with Connetics Corp. for ConXnT (scleroderma and organ fibrosis). Innovatech du Grand Montreal announced its intent to exercise its warrants
July
Paladin announced Lennie Ryer as CFO effective August 1st. Paladin signed an exclusive Canadian distribution deal with Biochem Pharma (now called Shire Pharmaceuticals Group plc) for PacisT, a treatment for bladder cancer.
June
Paladin issued 75,236 options to its officers and employees. Paladin acquired exclusive Canadian distribution rights for Antizol® (a treatment for antifreeze poisoning) from Orphan Medical, Inc.
May
Paladin announced 1998 year-end results with net revenues of $836,136 versus a loss of $1,006,013 for the previous year (1997).
February
Paladin acquired the exclusive Canadian distribution rights to Cystistat® (interstitial cystitis) and Suplasyn® (osteoarthritis) from Bioniche Life Sciences, Inc.
1998 - Summary
Paladin purchased Pharmascience's Innovative Business Unit. Mr. Ted Wise, co-founder of Pharmascience, joined Paladin as its Chairman. The Company developed its practice of focusing marketing and selling efforts on high prescribing specialists and purchasing rights to innovative products in select therapeutic areas. Paladin completed a $6 million private placement led by three prominent Canadian venture capital investors: Royal Bank Capital Corporation, BioCapital and Innovatech du Grand Montréal. Paladin posted record revenues of $6.2 million up from $0.849 million for the previous year and turned the corner on profitability ending the year with $0.836 million of net income.
1998 - Detail
November
Paladin purchased the Moi-StirT trademark from Solvay Pharma, Inc.
July
Paladin completed the acquisition of $13.9 million worth of products from Pharmascience and completes a $6 million private placement.
June
Paladin received approval from the Therapeutics Product Directorate (formerly the Health Protection Branch) for pms-Selegilene.
March
Paladin signed a Term Sheet with Royal Bank Capital Corporation. Paladin and Solvay Pharma, Inc. signed a second deal for a xerostomia product - the exclusive Canadian distribution rights for Sialor®.
January
Paladin announced an exercise of share purchase warrants by Joddes Limited ($750,000).
1997- Summary
Paladin began to develop its product line through the execution of an aggressive acquisition and licensing strategy. Several of its generic products received regulatory approval and were successfully launched. Paladin continued to invest in innovative drugs that are in the late stages of development and to acquire the Canadian distribution rights to innovative, patented products from U.S. and European biotech companies.
1997 - Detail
November
The HPB approved pms-Valproic Acid Syrup.
February
The HPB approved pms-Valproic Acid 250 mg capsules.
January
Paladin announced the exercise of share purchase warrants by 125567 Canada Inc.
1996 - Summary
The Company's new name was approved by the Vancouver Stock Exchange, and Mr. Goodman became Paladin's first employee. Later in the year, Mark Beaudet joined Paladin as a Director and a Vice President. Paladin acquired the Canadian rights to Statex®SR from Drug Royalty Corporation and to SYNSORB Pk® from SYNSORB Biotech Inc.
1996 - Detail
December
Paladin announced a distribution agreement with Drug Royalty Inc. for Statex®BID and Statex®QD. The HPB approved pms-Tryptophan 1-gram tablet.
September
The HPB approved pms-Valproic Acid 500 mg.
June
Paladin made a new application to the HPB for pms-Valproic Acid Syrup.
May
Paladin acquired pms-Lithium Carbonate from Pharmascience. The Vancouver Stock Exchange approved Paladin's name change and share consolidation plan.
March
The Health Protection Branch (now called the Therapeutics Product Directorate) approved pms-Lithium Carbonate.
January
Paladin completed the acquisition of a small number of generic products and a private placement.
1995 & Before - Summary
In 1995, Mr. Jonathan Ross Goodman joined Pharmascience Inc. (Pharmascience) to lead its Innovative Business Unit. Pharmascience, a prominent Canadian generic pharmaceutical manufacturer and distributor, planned to grow horizontally into the development and marketing of innovative, patented pharmaceuticals. Through a private market transaction, Pharmascience purchased a majority of shares in GeriatRx, a Vancouver Stock Exchange listed pharmaceutical company. GeriatRx subsequently completed a private placement with Pharmascience and Mr. Ted Wise, who then reorganized the management of the company. In order to secure a stable income stream for the Company during its development stage, the reorganized GeriatRx acquired a small number of generic products from Pharmascience in exchange for shares. The share purchase, private placement and sale of generic products to GeriatRx were the first steps in Pharmascience's creation of an independent Canadian specialty pharmaceutical company.
1983 to 1995 - Detail
December 1995
The Vancouver Stock Exchange approved the acquisition of the generic products and the private placement.
July 1995
Paladin signed a distribution agreement with Pharmascience for generic products. Jonathan Ross Goodman was appointed as President and CEO of Paladin Labs.
June 1995
The board of directors approved a change of the company's name to Paladin Labs Inc.
May 1995
GeriatRx announced the acquisition of a small number of generic products from Pharmascience. GeriatRx announced a private placement of $1 million for 6.6 million shares.
March 1995
Pharmascience purchased 1,058,404 shares of GeriatRx through a private market transaction. New officers and directors were appointed.
June 1985
GeriatRx began trading on the Vancouver Stock Exchange.
February 1983
GeriatRx incorporated as a British Columbia company.
|
